While smoking remains the leading cause of preventable death in the United States, emerging research continues to suggest a potential inverse relationship with Parkinson’s disease.
A recent large-scale longitudinal study adds new nuance to an already controversial topic in medicine. As these new findings gain attention, healthcare providers must balance interpreting interesting neurological data without undermining the importance of smoking cessation.
Here’s what the latest study found on smoking and Parkinson’s disease — and what it means for clinical practice.
What the Researchers Found
Current smoking is associated with a lower risk of Parkinson’s disease, while recent and sustained quitters have lower risks for all-cause mortality, according to a study published online Feb. 25 in Neurology.
Sung-Ho Ahn, from the Yonsei University College of Medicine in Seoul, South Korea, and colleagues conducted a large-scale retrospective cohort study involving current smokers aged 40 years or older to examine the association between longitudinal changes in smoking status and risks for PD and all-cause mortality. Participants were categorized into persistent smokers, recent quitters, sustained quitters, and relapsed smokers.
Data were included for 410,489 eligible participants. The researchers found that persistent smokers had the lowest risk of PD during a median 9.1-year follow-up. Higher risks of PD were seen for recent quitters and sustained quitters compared with persistent smokers (subdistribution hazard ratios [95 percent confidence intervals], 1.60 [1.41 to 1.82] and 1.61 [1.42 to 1.81], respectively); no significant difference was seen for relapsed smokers versus persistent smokers (subdistribution hazard ratio, 1.05; 95 percent confidence interval, 0.87 to 1.28). Recent and sustained quitters had 3 and 17 percent lower risks of all-cause mortality, respectively, compared with persistent smokers, while no significant difference was seen for relapsed smokers.
“Our study suggests a lower risk of Parkinson’s is not necessarily associated with how long someone smokes, but rather if they are currently smoking,” coauthor Jun-Hyuk Lee, M.D., Ph.D., from the Eulji University School of Medicine in Seoul, South Korea, said in a statement.
“Future studies are needed to better understand which components of smoking contribute to the reduced risk, and to develop safe and targeted therapies that replicate the effects of smoking for Parkinson’s without the harmful health consequences.”
Understanding the Smoking and Parkinson’s Disease Paradox
Multiple studies have examined the longstanding inverse relationship between smoking and Parkinson’s disease.
Several biological mechanisms can help explain this paradox:
- Nicotine: May act as a neuroprotective agent by stimulating nicotinic receptors and protecting neurons.
- Carbon monoxide: Low-dose exposure may protect against α-synuclein accumulation, a protein linked to Parkinson’s.
- MAO inhibitors: Certain compounds in tobacco smoke may inhibit MAO-B, potentially reducing neuronal damage.
Although these mechanisms may suggest possible protective effects, correlation doesn’t equal causation. Lifestyle, genetics, and survival bias remain important confounders.
Why This Does Not Change Smoking Guidance
Smoking continues to be a significant risk factor for cardiovascular disease, cancer, and premature death — making cessation crucial for all patients. Notably, this study also found that recent and sustained quitters had lower all-cause mortality (3 percent and 17 percent, respectively).
Any potential neurological association doesn’t outweigh the well-established systemic harms of smoking.
The research isn’t offering a new clinical recommendation — they highlight a complex association that requires further investigation.
Clinical Implications for Providers
For providers, this research underscores the importance of clear, contextual communication. Patients encounter headlines suggesting that smoking could lower their risk of Parkinson’s, and some may interpret this as a justification to continue or even start smoking. Clinicians should be prepared to address these misconceptions directly with their patients.
A helpful approach for providers is to acknowledge the research while reinforcing the broader evidence base. While some research suggests an inverse relationship between smoking and Parkinson’s disease, there’s an overwhelming body of evidence confirming that smoking significantly increases the risk of chronic disease and premature death.
Evidence-based smoking cessation strategies, such as behavioral counseling and medication, should remain the cornerstone of care.
What Comes Next in Research
The study’s findings also highlight an important step: identifying the mechanisms behind an observed association. Researchers are interested in exploring whether specific components of tobacco, such as nicotine, may influence dopamine pathways or offer some form of neuroprotection.
Until then, the current research should be viewed as a starting point for further investigation rather than a basis for clinical recommendations.
The Takeaway
The relationship between smoking and Parkinson’s disease remains complex and, at times, counterintuitive. While the latest research adds to a growing body of literature suggesting a link between current smoking and lower Parkinson’s disease risk, it also reinforces a critical reality: quitting smoking is still associated with improved overall survival.
For providers, the takeaway is not to interpret smoking as a protective factor against the neurological disease, but to approach emerging data with nuance and clarity. As more research comes out, clinicians play a key role in translating these findings into responsible, patient-centered guidance.
The ultimate goal is not to validate or encourage harmful behaviors, but to better understand disease progression and develop safer interventions that benefit patients.